Novel Gene Signature Reveals Prognostic Model in Acute Myeloid Leukemia

Frontiers in Genetics
Ying QuHong Zhou


Acute myeloid leukemia (AML) is a clonal malignant disease with poor prognosis and a low overall survival rate. Although many studies on the treatment and detection of AML have been conducted, the molecular mechanism of AML development and progression has not been fully elucidated. The present study was designed to pursuit the molecular mechanism of AML using a comprehensive bioinformatics analysis, and build an applicable model to predict the survival probability of AML patients in clinical use. To simplify the complicated regulatory networks, we performed the gene co-expression and PPI network based on WGCNA and STRING database using modularization design. Two machine learning methods, A least absolute shrinkage and selector operation (LASSO) algorithm and support vector machine-recursive feature elimination (SVM-RFE), were used to filter the common hub genes by five-fold cross-validation. The candidate hub genes were used to build the predictive model of AML by the cox-proportional hazards analysis, and validated in The Cancer Genome Atlas (TCGA) cohort and ohsu cohort, which were reliable in the experimental verification by qRT-PCR and western blotting in mRNA and protein levels. Three hub genes, FLT3, CD177 and TTPAL were ...Continue Reading


May 18, 2001·Nature·P Blume-Jensen, T Hunter
Jan 10, 2002·Genome Research·Ronald JansenMark Gerstein
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Mar 12, 2002·British Journal of Haematology·John T Reilly
Aug 31, 2002·Science·E RavaszA L Barabási
Oct 4, 2005·Proceedings of the National Academy of Sciences of the United States of America·Aravind SubramanianJill P Mesirov
Apr 7, 2006·Leukemia·N BoisselUNKNOWN Leucémies Aiguës Myéloblastiques de l'Enfant (LAME) Cooperative Groups
Apr 25, 2006·Biostatistics·W Evan JohnsonAriel Rabinovic
Nov 21, 2007·Bioinformatics·Peter LangfelderSteve Horvath
Dec 31, 2008·BMC Bioinformatics·Peter Langfelder, Steve Horvath
Mar 30, 2012·Omics : a Journal of Integrative Biology·Guangchuang YuQing-Yu He
Oct 9, 2014·TheScientificWorldJournal·Mei-Ling HuangBo-Ru Jiang
Oct 30, 2014·Nucleic Acids Research·Damian SzklarczykChristian von Mering
Jan 22, 2015·Nucleic Acids Research·Matthew E RitchieGordon K Smyth
Nov 17, 2015·Cell Death Discovery·Alexander S WatsonAnna Katharina Simon
Sep 11, 2016·Journal of Hematology & Oncology·Rosalia de Necochea-CampionChien-Shing Chen
Feb 22, 2017·Stem Cell Investigation·Jianbiao Zhou, Wee-Joo Chng
Oct 20, 2018·Nature·Jeffrey W TynerBrian J Druker
Mar 31, 2019·Seminars in Hematology·Sheng F Cai, Ross L Levine
May 13, 2019·Current Hematologic Malignancy Reports·Jennifer E VaughnRoland B Walter
May 22, 2019·Blood Reviews·Panupong HansrivijitStefan O Ciurea
May 28, 2019·Journal of Hematology & Oncology·Yan LiuLin Fu

❮ Previous
Next ❯


❮ Previous
Next ❯

Datasets Mentioned


Methods Mentioned


Software Mentioned


Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.